Rituximab in Rheumatoid Arthritis Lung Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions
Rheumatoid ArthritisInterstitial Pneumonia
Interventions
DRUG

Rituximab

Rituximab 1000 mg. I.V.on each days 1 and 15 with repeat dosing at 6 months.

Trial Locations (2)

55905

Mayo Clinic, Rochester

02115

Brigham and Women's Hospital, Boston

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

National Center for Research Resources (NCRR)

NIH

lead

Eric Matteson

OTHER

NCT00578565 - Rituximab in Rheumatoid Arthritis Lung Disease | Biotech Hunter | Biotech Hunter